Comorbidities in ADHD children treated with methylphenidate: a database study.
Angela A Kraut1, Ingo Langner, Christina Lindemann
1Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
BMC Psychiatry
|January 9, 2013
Summary
Methylphenidate (MPH) is a common ADHD treatment, but many children prescribed it have pre-existing psychiatric conditions. Cardiovascular issues were also more common in MPH users, highlighting the need to weigh risks versus benefits.
Area of Science:
- Pediatric Pharmacology
- Pharmacoepidemiology
- Child Psychiatry
Background:
- Methylphenidate (MPH) is the primary pharmacological treatment for attention deficit / hyperactivity disorder (ADHD) in children.
- MPH use is contraindicated with certain psychiatric, cerebrovascular, and cardiovascular conditions.
- Understanding MPH treatment prevalence and associated comorbidities is crucial for safe prescribing practices.
Purpose of the Study:
- To assess the prevalence and incidence of Methylphenidate (MPH) treatment in children and adolescents in Germany.
- To determine the frequency of contraindicating psychiatric, cerebrovascular, and cardiovascular comorbidities in new MPH users compared to a control group.
- To inform risk-benefit assessments for MPH therapy in pediatric ADHD management.
Main Methods:
- Utilized German Pharmacoepidemiological Research Database (GePaRD) data from 2004-2006.
- Assessed MPH treatment prevalence and incidence based on prescription data.
- Analyzed comorbidities in new MPH users and a control group using logistic regression.
Main Results:
- In 2005, 1.5% of German children aged 3-17 received MPH (2.3% males, 0.6% females).
- 83% of new MPH users had a preceding psychiatric comorbidity, versus 20% in controls.
- While rare, cerebro- and cardiovascular comorbidities were more frequent in MPH users (2%) than controls (1.2%).
Conclusions:
- This study provides the first age-specific incidence rates for MPH in Germany.
- A significant proportion of children initiating MPH treatment had pre-existing psychiatric comorbidities.
- The higher prevalence of cardiovascular conditions in MPH users necessitates careful risk-benefit evaluation for MPH treatment in children with ADHD and comorbidities.
More Related Videos
05:32Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
Published on: December 7, 2018
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:26Modeling in Therapy
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.